Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1111/j.1463-1326.2009.01173.x.
J Rosenstock, H Yki-Järvinen, W T Cefalu, Y Chen, E Luo, B Musser, P J Andryuk, Y Ling, K D Kaufman, J M Amatruda, S S Engel, L Katz
Affiliations
- PMID: 20092585
- DOI: 10.1111/j.1463-1326.2009.01173.x
Randomized Controlled Trial
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T Vilsbøll et al. Diabetes Obes Metab. 2010 Feb.
Abstract
Objective: To evaluate the efficacy and tolerability of sitagliptin when added to insulin therapy alone or in combination with metformin in patients with type 2 diabetes.
Methods: After a 2 week placebo run-in period, eligible patients inadequately controlled on long-acting, intermediate-acting or premixed insulin (HbA1c > or = 7.5% and < or = 11%), were randomised 1:1 to the addition of once-daily sitagliptin 100 mg or matching placebo over a 24-week study period. The study capped the proportion of randomised patients on insulin plus metformin at 75%. Further, the study capped the proportion of randomised patients on premixed insulin at 25%. The metformin dose and the insulin dose were to remain stable throughout the study. The primary endpoint was HbA1c change from baseline at week 24.
Results: Mean baseline characteristics were similar between the sitagliptin (n = 322) and placebo (n = 319) groups, including HbA1c (8.7 vs. 8.6%), diabetes duration (13 vs. 12 years), body mass index (31.4 vs. 31.4 kg/m(2)), and total daily insulin dose (51 vs. 52 IU), respectively. At 24 weeks, the addition of sitagliptin significantly (p < 0.001) reduced HbA1c by 0.6% compared with placebo (0.0%). A greater proportion of patients achieved an HbA1c level < 7% while randomised to sitagliptin as compared with placebo (13 vs. 5% respectively; p < 0.001). Similar HbA1c reductions were observed in the patient strata defined by insulin type (long-acting and intermediate-acting insulins or premixed insulins) and by baseline metformin treatment. The addition of sitagliptin significantly (p < 0.001) reduced fasting plasma glucose by 15.0 mg/dl (0.8 mmol/l) and 2-h postmeal glucose by 36.1 mg/dl (2.0 mmol/l) relative to placebo. A higher incidence of adverse experiences was reported with sitagliptin (52%) compared with placebo (43%), due mainly to the increased incidence of hypoglycaemia (sitagliptin, 16% vs. placebo, 8%). The number of hypoglycaemic events meeting the protocol-specified criteria for severity was low with sitagliptin (n = 2) and placebo (n = 1). No significant change from baseline in body weight was observed in either group.
Conclusion: In this 24-week study, the addition of sitagliptin to ongoing, stable-dose insulin therapy with or without concomitant metformin improved glycaemic control and was generally well tolerated in patients with type 2 diabetes.
Similar articles
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G. Lavalle-González FJ, et al. Diabetologia. 2013 Dec;56(12):2582-92. doi: 10.1007/s00125-013-3039-1. Epub 2013 Sep 13. Diabetologia. 2013. PMID: 24026211 Free PMC article. Clinical Trial. - Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ. Wainstein J, et al. Diabetes Obes Metab. 2012 May;14(5):409-18. doi: 10.1111/j.1463-1326.2011.01530.x. Epub 2011 Dec 22. Diabetes Obes Metab. 2012. PMID: 22059736 Clinical Trial. - Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Jabbour SA, Hardy E, Sugg J, Parikh S; Study 10 Group. Jabbour SA, et al. Diabetes Care. 2014;37(3):740-50. doi: 10.2337/dc13-0467. Epub 2013 Oct 21. Diabetes Care. 2014. PMID: 24144654 Clinical Trial. - Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
Chwieduk CM. Chwieduk CM. Drugs. 2011 Feb 12;71(3):349-61. doi: 10.2165/11206060-000000000-00000. Drugs. 2011. PMID: 21319871 Review. - [Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Schnell O. Schnell O. Dtsch Med Wochenschr. 2014 Feb;139 Suppl 2:S70-4. doi: 10.1055/s-0033-1359996. Epub 2014 Jan 30. Dtsch Med Wochenschr. 2014. PMID: 24481636 Review. German. No abstract available.
Cited by
- Impact of concomitant oral glucose-lowering medications on the success of basal insulin titration in insulin-naïve patients with type 2 diabetes: a systematic analysis.
Wollenhaupt D, Wolters J, Abd El Aziz M, Nauck MA. Wollenhaupt D, et al. BMJ Open Diabetes Res Care. 2023 Jul;11(4):e003296. doi: 10.1136/bmjdrc-2022-003296. BMJ Open Diabetes Res Care. 2023. PMID: 37433696 Free PMC article. Review. - Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study.
Nagao M, Sasaki J, Sugihara H, Tanimura-Inagaki K, Harada T, Sakuma I, Oikawa S; STREAM Study Investigators. Nagao M, et al. Sci Rep. 2023 Jan 4;13(1):134. doi: 10.1038/s41598-022-27301-9. Sci Rep. 2023. PMID: 36599895 Free PMC article. Clinical Trial. - American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV Jr, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. Blonde L, et al. Endocr Pract. 2022 Oct;28(10):923-1049. doi: 10.1016/j.eprac.2022.08.002. Epub 2022 Aug 11. Endocr Pract. 2022. PMID: 35963508 Free PMC article. - Impact of the Fasting Plasma Glucose Titration Target on the Success of Basal Insulin Titration in Insulin-Naïve Patients with Type 2 Diabetes: A Systematic Analysis.
Wolters J, Wollenhaupt D, El Aziz MA, Nauck MA. Wolters J, et al. J Diabetes Res. 2022 Jul 30;2022:4758042. doi: 10.1155/2022/4758042. eCollection 2022. J Diabetes Res. 2022. PMID: 35942330 Free PMC article. - Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.
He L, Wang J, Ping F, Yang N, Huang J, Li W, Xu L, Zhang H, Li Y. He L, et al. BMJ. 2022 Jun 28;377:e068882. doi: 10.1136/bmj-2021-068882. BMJ. 2022. PMID: 35764326 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical